CAMBRIDGE, Mass., Jan. 23, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a Phase 1 dose-escalating clinical study of MM-398 in conjunction with cyclophosphamide for the treatment of pediatric solid tumors. MM-398 is a stable nanoliposomal irinotecan that is designed to exploit leaky tumor vasculature for enhanced drug delivery to tumors.
Help employers find you! Check out all the jobs and post your resume.
